UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren\'s Syndrome (pSS). The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.
Epistemonikos ID: 6e2e90f71a00bdaa333847a19ef38521048d2f4b
First added on: May 12, 2024